Clinda-VC

Clindamycin (Cap: HCl; Inj: Phosphate).

Each capsule contains Clindamycin HCl equivalent to Clindamycin 300 mg. Each 1 ml contains Clindamycin phosphate equivalent to Clindamycin 150 mg.

Mechanism of action: Clindamycin is a lincosamide antibiotic with a primarily bacteriostatic action against gram-positive including streptococci, staphylococci, Bacillus anthracis, and Corynebacterium diphtheriae and a wide range of anaerobic bacteria. Susceptible gram-positive anaerobes including Eubacterium, Propionibacterium, Peptococcus, and Peptostreptococcus spp., and many strains of Clostridium perfringens and Cl. tetani. Among Gram-negative anaerobes susceptible to clindamycin are Fusobacterium spp., Veillonella, and Bacteroides spp., including the B. fragilis group.
Clindamycin is usually considered bacteriostatic by binding to the 50 S subunits of bacterial ribosomes and preventing peptide bond formation, cause inhibition of protein synthesis in susceptible bacteria. Clindamycin may be bactericidal in high concentrations. When used against highly susceptible organisms Clindamycin may be bactericidal antibiotic.

For treatment of bacterial infections caused by susceptible microorganism i.e.: As an adjunctive treatment of chronic bone and joint infections, and acute hematogenous osteomyelitis caused by staphylococci.
Female pelvic infections, including endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infections caused by anaerobes.
Intra-abdominal infections such as peritonitis and abscesses caused by anaerobes.
Pneumonia including serious respiratory tract infections (such as empyema, pneumonitis, and lung abscesses) caused by anaerobes.
Septicemia caused by streptococci and staphylococci.
Skin and soft tissue infections caused by anaerobes, streptococci, and staphylococci.

Usual adult and adolescent dose: For antibacterial: Intramuscular or intravenous.
Serious infections: 150-300 mg every 6 hours.
More serious infections: 300 to 600 mg (base).
(Single intramuscular injections of greater than 600 mg are not recommended and dosage should not exceed 2.7 gm daily).
Usual pediatric dose: For antibacterial: Intramuscular or intravenous.
Serious infections: 8-16 mg/kg/day divided into 3-4 doses given every 6 hours.
More serious infections: 16-20 mg/kg/day divided into 3-4 doses given every 6 hours.

It is contra-indicated in patients who are hypersensitive to clindamycin or lincomycin.
Aminoglycosides are associated with clindamycin significance nephrotoxicity and ototoxicity.
It should be used with caution in patient who have a history of gastrointestinal disease, particularly ulcerative colitis, or severe hepatic function impairment.
Monitoring of renal and 8^th cranial nerve function at onset of therapy and at regular interval are essential especially for patients with suspected renal impairment.
Avoid concomitant use with other ototoxic, neurotoxic or nephrotoxic drugs.
Dehydration and advanced age may increase risk of toxicities.
Use in Children: Benzyl alcohol in the product has been associated with a fatal 'gasping syndrome' in premature infants.
Not recommended for use in children under 2 years of age.
Use in Pregnancy: Avoid using clindamycin in pregnant woman (Category D) unless benefit outweighs the risk.

Avoid using clindamycin in pregnant woman (Category D) unless benefit outweighs the risk.

1. Hypersensitivity (skin rash, redness, and itching).
2. Pseudomembranous colitis (severe abdominal or stomach cramps and pain; abdominal tenderness; diarrhea, watery and severe, which may also be bloody; fever).
3. Gastrointestinal disturbances (abdominal pain; diarrhea; nausea and vomiting).

Incompatibilities: Clindamycin phosphate is physically incompatible with ampicillin, phenytoin sodium, barbiturates, aminophylline, calcium gluconate, and magnesium sulfate.
Preparation of dosage form: To prepare initial dilution for intravenous use, each dose must be diluted as follows. (See table.)

Click on icon to see table/diagram/image

Protected from light at temperature not exceeding 25°C. Do not refrigerate.

Other Antibiotics

J01FF01 - clindamycin ; Belongs to the class of lincosamides. Used in the systemic treatment of infections.

Cap: D; Inj: S